GDTC
HEALTHCARECytoMed Therapeutics Ltd
$0.92+0.00 (+0.00%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving GDTC Today?
No stock-specific AI insight has been generated for GDTC yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.72$3.68
$0.92
Fundamentals
Market Cap$11M
P/E Ratio—
EPS$-0.27
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume24K
Avg Volume (10D)—
Shares Outstanding11.8M
GDTC News
13 articles- CytoMed Therapeutics And 2 More Penny Stocks With Promising ProspectsYahoo Finance·Feb 6, 2026
- Cytomed Therapeutics refutes ‘misleading’ claims, reaffirms clinical progressYahoo Finance·Jan 29, 2026
- CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical ProgressYahoo Finance·Jan 28, 2026
- CytoMed Therapeutics’ new year update and seeks shareholders’ feedback on proposal to improve shareholder value for their patient capitalYahoo Finance·Jan 13, 2026
- CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Treat Cancers in MalaysiaYahoo Finance·Dec 8, 2025
- CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and IndiaYahoo Finance·Nov 18, 2025
- CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China StrategyYahoo Finance·Nov 6, 2025
- CytoMed Therapeutics’ Chairman Increases Effective Holdings to 21.95%Yahoo Finance·Oct 22, 2025
- CytoMed makes cash bid for potential acquisition of TC BioPharm Limited’s relevant assetsYahoo Finance·Oct 14, 2025
- CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid LeukemiaYahoo Finance·Oct 2, 2025
- Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisitionYahoo Finance·Aug 28, 2025
- CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering ProgramYahoo Finance·Aug 19, 2025
- Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological MalignanciesYahoo Finance·Jul 21, 2025
All 13 articles loaded
Price Data
Open$0.98
Previous Close$0.92
Day High$0.98
Day Low$0.90
52 Week High$3.68
52 Week Low$0.72
52-Week Range
$0.72$3.68
$0.92
Fundamentals
Market Cap$11M
P/E Ratio—
EPS$-0.27
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume24K
Avg Volume (10D)—
Shares Outstanding11.8M
About CytoMed Therapeutics Ltd
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company is headquartered in Singapore.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—